Hemant N. Joshi, Ph.D., MBA

Articles by Hemant N. Joshi, Ph.D., MBA

  • A Quarterly Review of NDAs – October-December 2020

    Friday, March 12, 2021
    This quarterly review on New Drug Applications contain data for applications approved during the fourth quarter of 2020, which includes New Molecular Entities (NMEs), new biologics, etc.
  • HORIZON LINES A Quarterly Review of NDAs – July-September 2020

    Thursday, December 17, 2020
    This quarterly review on New Drug Applications (NDAs) contains data for applications approved for the first-time during July-September 2020, which includes New Molecular Entities (NMEs) and new biologics. A total of 36 applications were approved by ...
  • HORIZON LINES: A Quarterly Review of NDAs – April-June 2020

    Thursday, September 24, 2020
    This quarterly review on New Drug Applications contains data for applications approved for the first time during April-June of 2020, which includes New Molecular Entities (NMEs) and new biologics. A total of 43 applications were approved by FDA ...
  • HORIZON LINES: A Quarterly Review of NDAs – April-June 2020

    Friday, May 29, 2020
    This quarterly review on new drug applications contains data for applications approved for the first time during the first quarter of 2020 which includes New Molecular Entities (NMEs) and new biologics. A total of 30 applications were approved by the...
  • HORIZON LINES: A Quarterly Review of NDAs –July-September 2019

    Monday, December 09, 2019
    This quarterly review of new drug applications contain data for applications approved for the first time during the third quarter of 2019 which includes New Molecular Entities (NMEs) and new biologics. A total of 36 applications were approved by the ...
  • HORIZON LINES: A Quarterly Review of NDAs – April-June 2019

    Tuesday, September 24, 2019
    This quarterly review on new drug applications contain data for applications approved for the first time during the second quarter of 2019 which includes new molecular entities (NMEs) and new biologics. A total of 30 applications were approved by FDA...
  • HORIZON LINES: A Quarterly Review of New Drug Applications – October-December 2018

    Thursday, March 21, 2019
    This quarterly review on new drug applications contains data for applications approved for the first time during the fourth quarter of 2018 which includes New Molecular Entities (NMEs) and new biologics. A total of 46 applications were approved by ...
  • HORIZON LINES: A Quarterly Review of NDAs – April-June, 2018

    Thursday, October 11, 2018
    This quarterly review on New Drug Applications (NDAs) contain data for applications approved for the first time during the second quarter of 2018, which includes New Molecular Entities (NMEs) and new biologics.
  • HORIZON LINES: A Quarterly Review of NDAs October 2017 – December 2017

    Tuesday, March 20, 2018
    This column summarizes newly approved drugs, biologics, new indications and patient populations for already approved drugs from October to December 2017. This includes New Drug Applications (NDAs), Biologics Licensing Applications (BLAs) and ...
  • HORIZON LINES: A Quarterly Review of NDAs June – September, 2017

    Saturday, February 10, 2018
    This column summarizes newly approved drugs and new indications and patient population for already approved drugs from June to September 2017. This includes New Drug Applications (NDAs), Biologics Licensing Applications (BLAs) and Biosimilar ...
Page